Moreover, since TMUCIH was one of the best cancer centers in northern China, the bias of patients' self‐selection would also lead to more HER2‐low BC admitted to TMUCIH in the hope of more opportunities for potential targeted therapies specifically associated with HER2‐low BC. The gene discussed is ERBB2; the disease is cancer.